ROCHESTER, N.Y. , Jan. 8 /PRNewswire-USNewswire/ -- The
The company's technology platform -- called NanoLantern -- is a novel method of identifying genetic sequences from biological samples, a process that can be used to detect any organism or genetic feature by identifying its unique DNA fingerprint. The NanoLantern consists of an array of DNA probes that can be programmed from a database of known genetic signatures to simultaneously screen for multiple individual targets using a single sample of blood, urine, cells, or other substance with organic content. The U.S. patent is being awarded for the process the technology uses to identify DNA sequences. The method, first developed by
"This patent represents an important milestone in developing the company's intellectual property portfolio," said Rand Henke , CEO of Lighthouse Biosciences. "It addresses a breakthrough method that will allow the company to design and make at a low cost a very wide range of probes for the detection of most pathogens."
The company is in the process of developing a prototype that consists of a series of disposable biosensor cartridges -- or labs on a chip -- that will be housed in a workstation that can be deployed in hospitals, doctor's offices, nursing homes, or any other health care setting.
While the technology has a wide array of potential applications in healthcare, agriculture, food safety, water quality, and national security, Lighthouse Biosciences is initially focused on the field of hospital-acquired infections (HAI). HAI are infections that patients receive during their care -- in a hospital or other health care facility such as a nursing home -- that are not related to any pre-existing medical condition. Despite extensive efforts in recent years to address the causes, HAI remain a massive burden on the U.S. health care system with more than 1 million annual cases and 90,000 associated deaths, all at a healthcare cost of
One of the key challenges in combating HAI is the need to develop a system of surveillance that can identify these infections as early as possible. The current standard is to send potentially infectious samples out to a clinical laboratory for analysis and wait for the results. This process typically takes up to 2 to 3 days depending upon the proximity of the lab to the health care facility and the speed at which the lab can process the samples, a delay that can be an impediment to successful treatment. The NanoLantern technology has demonstrated the ability to provide results rapidly -- within 15 minutes -- and do so at the point of care.
The largest category of HAIs is urinary tract infections, which account for 40% of all infections. Lighthouse Biosciences, in cooperation with the URMC Departments of Urology and Microbiology and Immunology is currently conducting clinical studies to test the screening system at URMC's Strong Memorial Hospital.
The underlying technology for the company's NanoLantern(TM) platform was first developed by
About the University of Rochester Medical Center
One of the nation's top academic medical centers, the
About Lighthouse Biosciences, LLC
Lighthouse Biosciences, LLC is an early-stage, molecular in vitro diagnostic company located in Rochester, NY . Based on its proprietary NanoLantern(TM) platform, Lighthouse is developing breakthrough diagnostic solutions that are much faster, more accurate, simpler, and less expensive than currently used diagnostics. Additionally, the NanoLantern(TM) technology enables multiple tests on a single sample for simultaneous and very reliable results. Lighthouse solutions consist of "lab on chip" disposable cartridges that contain highly targeted detection probes and sample chemistry and a desktop reader workstation for preparing and presenting test results. Lighthouse expects its product solutions are small and simple enough to deploy throughout decentralized environments, like point-of-care healthcare locations, and are scalable to serve the high-volume needs of centralized laboratories.